Skin cancer vaccine BLA submitted by March 31, 2027?
No live price for this market yet.
Decided by major news reports, by March 31, 2027.
Research, not financial advice. Prices from Polymarket’s international site, not available in the US.
Possible results
There is no live market linked to this card yet, so there are no prices to show.
The one trap›
The rules don’t list special cases like delays or cancellations. The venue’s own rules decide anything unusual.
Show details for experienced traders
The details
No live order bookRule note: the announcement countsNo single official source
Chance the crowd gives Yes
-
no live price
Yes orders vs No orders near the price
-
no order list read
Fine-print risk
Medium (30/100)
settles on the official announcement
Price and trading: no live Polymarket price or order book is tracked for this contract yet.
Official source: settlement runs on Consensus of credible reporting (no single named data provider). Has no single feed: settlement relies on consensus reporting. No recorded moves for this market yet.
Fine print: A qualifying official announcement settles Yes; implementation is not required. Deadline: Wed, Mar 31, 2027, 11:59 PM ET.
Source named: Consensus of credible reporting (not a tracked official feed, no release history)
Standardized read of public order book, official-source and contract-rule data, identical for every viewer. It describes the data and is not a recommendation. The venue’s published rules control settlement.
Key lines from the rules (Polymarket)
“This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the…”
“The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a…”
“If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or…”
